Study On Multidrug Resistance Of Nanodrug Delivery System

The multidrug resistance of cancer is an important reason to hinder its cure.The commonly used clinical anti-cancer drugs are mostly hydrophobic small molecule drugs,which have poor biocompatibility,do not have targeting properties,and have many side effects during treatment.With the development of nanotechnology,it becomes possible to achieve controlled release of drugs and target target sites.This article focuses on the treatment of multi-drug resistant tumors and is divided into two parts.The first part is to polymerize the polymer with reducing response through the mechanism of ATRP reaction,which can release a large amount of drug in the tumor site containing high concentration of glutathione.Both the carrier and the prodrug contain tocopherol succinate,which can not only increase the drug loading rate,but also inhibit the P-gp glycoprotein activity of drug-resistant cells.The fragmentation of the vector consumes most of the glutathione and reduces the inactivating effect of intracellular glutathione on the cisplatin drug.The drug loading system solves the problem of multidrug resistance from these two aspects.Finally,the results from the animal tumor model proved that the nano drug delivery system has a good therapeutic ability.The second part focuses on the use of multiple drug combinations to inhibit drug resistance in order to avoid the acquisition of acquired drug resistance during single dosing.Firstly,multiple drug-loaded nanoparticles with high drug-loading stability were prepared.The drug-responsive nanoparticles with good synergism were screened and screened for their inhibitory effects in a variety of cells including drug-resistant and non-resistant cell lines.Finally,the results from the animal tumor model show that the combination of multiple drugs has obvious advantages in the treatment of multi-drug resistant tumors.